Exelixis ((EXEL)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Exelixis has initiated a Phase 1 study titled ‘A Phase 1 Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors.’ The study aims to evaluate the safety and optimal dosing of XB628, a novel bispecific antibody designed to engage natural killer cells by targeting NKG2A and PD-L1. This research is significant as it explores a first-in-class treatment option for challenging cancer types.
The intervention being tested is XB628, administered via intravenous infusion. XB628 is a biological treatment intended to activate the immune system against cancer cells by engaging natural killer cells.
The study follows an interventional design with a sequential intervention model. There is no masking involved, and the primary purpose is treatment. The study is focused on determining the maximum tolerated dose of XB628.
Key dates for the study include a start date of May 1, 2025, with the latest update provided on July 24, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
The market implications of this study are potentially significant for Exelixis, as successful results could enhance their competitive position in the oncology sector. Positive outcomes might boost investor confidence and stock performance, particularly as the industry seeks innovative cancer treatments.
The study is currently ongoing, with further details available on the ClinicalTrials portal.